Shenzhen Salubris Pharmaceuticals Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 4.97%

Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has an Asset Resilience Ratio of 4.97% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002294 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥545.66 Million
≈ $79.85 Million USD Cash + Short-term Investments

Total Assets

CN¥10.98 Billion
≈ $1.61 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Shenzhen Salubris Pharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Shenzhen Salubris Pharmaceuticals Co Ltd.

Liquid Assets Composition Over Time

This chart breaks down Shenzhen Salubris Pharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Shenzhen Salubris Pharmaceuticals Co Ltd to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥545.66 Million 4.97%
Total Liquid Assets CN¥545.66 Million 4.97%

Asset Resilience Insights

  • Limited Liquidity: Shenzhen Salubris Pharmaceuticals Co Ltd maintains only 4.97% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shenzhen Salubris Pharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shenzhen Salubris Pharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Kamada
TA:KMDA
Drug Manufacturers - Specialty & Generic 0.00%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Viatris Inc
NASDAQ:VTRS
Drug Manufacturers - Specialty & Generic 1.48%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
Drug Manufacturers - Specialty & Generic 1.01%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Drug Manufacturers - Specialty & Generic 5.90%

Annual Asset Resilience Ratio for Shenzhen Salubris Pharmaceuticals Co Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Shenzhen Salubris Pharmaceuticals Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 7.01% CN¥733.86 Million
≈ $107.39 Million
CN¥10.47 Billion
≈ $1.53 Billion
-2.37pp
2023-12-31 9.38% CN¥881.57 Million
≈ $129.00 Million
CN¥9.40 Billion
≈ $1.38 Billion
+6.02pp
2022-12-31 3.37% CN¥328.36 Million
≈ $48.05 Million
CN¥9.76 Billion
≈ $1.43 Billion
+2.72pp
2021-12-31 0.65% CN¥60.00 Million
≈ $8.78 Million
CN¥9.24 Billion
≈ $1.35 Billion
-2.45pp
2020-12-31 3.10% CN¥214.59 Million
≈ $31.40 Million
CN¥6.92 Billion
≈ $1.01 Billion
+0.41pp
2019-12-31 2.69% CN¥208.00 Million
≈ $30.44 Million
CN¥7.73 Billion
≈ $1.13 Billion
-4.90pp
2018-12-31 7.59% CN¥600.00 Million
≈ $87.80 Million
CN¥7.90 Billion
≈ $1.16 Billion
-4.79pp
2017-12-31 12.38% CN¥850.00 Million
≈ $124.38 Million
CN¥6.86 Billion
≈ $1.00 Billion
+11.39pp
2016-12-31 0.99% CN¥65.00 Million
≈ $9.51 Million
CN¥6.53 Billion
≈ $956.15 Million
+0.62pp
2015-12-31 0.37% CN¥20.00 Million
≈ $2.93 Million
CN¥5.39 Billion
≈ $788.27 Million
-4.18pp
2014-12-31 4.55% CN¥210.00 Million
≈ $30.73 Million
CN¥4.62 Billion
≈ $675.47 Million
--
pp = percentage points

About Shenzhen Salubris Pharmaceuticals Co Ltd

SHE:002294 China Drug Manufacturers - Specialty & Generic
Market Cap
$4.92 Billion
CN¥33.66 Billion CNY
Market Cap Rank
#3608 Global
#495 in China
Share Price
CN¥30.19
Change (1 day)
+1.38%
52-Week Range
CN¥29.60 - CN¥68.30
All Time High
CN¥68.30
About

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubit… Read more